Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

Completed

• Conditions: Carcinoma, Non-Small-Cell Lung; Immunotherapy

• Registration Number: NCT05321212
• Lead Sponsor: University Hospital, Brest

Brief Summary

This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-02
• Primary Completion: 2019-01-02
• Study Completion: 2019-03-02
• Study First Submitted: 2019-08-07
• Status Verified: 2022-04
• Study First Submitted QC: 2022-04-01
• Last Update Submitted: 2022-04-01
• Study First Posted: 2022-04-11
• Last Update Posted: 2022-04-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

• histologically or cytologically confirmed NSCLC PD- L1 TPS ≥ 50% stage III and IV WHO performance status of 0, 1 or 2 adequate organ function

Exclusion Criteria

• previous EGFR or ALK aberrations positive test for hepatitis B or C virus indicating acute or chronic infection known history of testing positive for human immunodeficiency virus (HIV) severe, uncontrolled autoimmune disease.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression free survival with pembrolizumab	time from initiation of pembrolizumab to the date of disease progression or death ( 20 months)	time from initiation of pembrolizumab to the date of disease progression or death

Trial Locations

Locations (2)

CHRU de Brest; 🇫🇷 Brest, France

CHIC de QUIMPER; 🇫🇷 Quimper, France